Experienced in Kaposi Sarcoma

Marc F. Van Der Valk

Amsterdam, NH, NL 
Experienced in Kaposi Sarcoma
Amsterdam, NH, NL 
OverviewLocationsClinical Research

Overview

Marc Van Der Valk practices in Amsterdam, Netherlands. Mr. Van Der Valk is rated as an Experienced expert by MediFind in the treatment of Kaposi Sarcoma. His top areas of expertise are HIV/AIDS, Hepatitis C, Hepatitis, and Hepatitis B.

His clinical research consists of co-authoring 172 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Kaposi Sarcoma.

Gender
Male

Locations

Amsterdam, NH, Netherlands
Other Locations
Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months From a Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed
A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months From a Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed
Enrollment Status: Completed
Publish Date: June 04, 2024
Intervention Type: Drug
Study Drugs: Cabotegravir, Rilpivirine, BIKTARVY
Study Phase: Phase 3
A Phase IIIb, Open-label, Hybrid Type III Trial Evaluating Implementation Strategies for Long-acting Cabotegravir Plus Long-acting Rilpivirine Every Two Months in HIV-1 Infected, Virologically Suppressed Adults in Select European Healthcare Settings
A Phase IIIb, Open-label, Hybrid Type III Trial Evaluating Implementation Strategies for Long-acting Cabotegravir Plus Long-acting Rilpivirine Every Two Months in HIV-1 Infected, Virologically Suppressed Adults in Select European Healthcare Settings
Enrollment Status: Completed
Publish Date: April 05, 2024
Intervention Type: Drug, Other
Study Drug: Cabotegravir
Study Phase: Phase 3
View 1 Less Clinical Trial

172 Total Publications

Perceptions and Experiences of HIV Nurses on Peer Support for People Living With HIV in the Netherlands: A Qualitative Study.
Perceptions and Experiences of HIV Nurses on Peer Support for People Living With HIV in the Netherlands: A Qualitative Study.
Journal: Journal of the International Association of Providers of AIDS Care
Published: September 04, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Van Der Valk's expertise for a condition
ConditionClose
      View All 12 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile